Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HMGCR | P04035 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870738 | 1.00 | KDM4E (0.69) | KDM4EHTTCYP3A4GAALCK | |
| SCHEMBL26027709 | 0.90 | KDM4E (0.56) | KDM4EHTTCYP3A4GAALCK | |
| SCHEMBL7300064 | 0.88 | TSHR (0.62) | KDM4EHTTCYP3A4GAARAB9A | |
| SCHEMBL7291805 | 0.88 | TSHR (0.62) | KDM4EHTTCYP3A4GAARAB9A | |
| SCHEMBL16285129 | 0.87 | KDM4E (0.54) | KDM4EHTTCYP3A4GAALCK | |
| SCHEMBL21753969 | 0.87 | KDM4E (0.54) | KDM4EHTTCYP3A4GAALCK | |
| SCHEMBL12793494 | 0.86 | HTT (0.56) | KDM4EHTTCYP3A4GAALMNA | |
| SCHEMBL10520470 | 0.86 | KDM4E (0.53) | KDM4EHTTCYP3A4GAAPOLB | |
| SCHEMBL4770365 | 0.85 | KDM4E (0.53) | KDM4EHTTCYP3A4GAAPOLB | |
| SCHEMBL6096678 | 0.85 | KDM4E (0.53) | KDM4EHTTCYP3A4GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532116-B | Synthesis method of anti-tumor targeted therapeutic drug tivozanib | WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD | 2015-01-21 | — | — | CN | claimed |
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | claimed |
| US-5672352-A | Methods of identifying the avian repellent effects of a compound and methods of repelling birds from materials susceptible to consumption by birds | MONELL CHEMICAL SENSES CENTER (US) | 1997-09-30 | — | — | US | claimed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| WO-2025062157-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240139125-A1 | BI-1 ANTAGONISTS AND THEIR USES | INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITY (KR) | 2024-05-02 | — | — | US | disclosed |
| CN-117800922-A | SOS1 inhibitors | 北京望实智慧科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-0107398-B1 | ORTHO SUBSTITUTED DIHYDROXY-2(1H)QUINAZOLINONE-1-ALKANOIC ACIDS | ORTHO PHARMA CORP (US) | 1988-06-08 | — | — | EP | disclosed |
| US-4645836-A | Process for the preparation of 6,7-dihydroxy-4-alkyl-2(1H) quinazolinone-1-propionic acids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-02-24 | — | — | US | disclosed |
| US-4631283-A | RENAL VASODILATORS, CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-12-23 | — | — | US | disclosed |
| US-4556739-A | QUINAZOLINONE INTERMEDIATES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-12-03 | — | — | US | disclosed |
| US-4555570-A | Substituted 4-alkyl-2-(1H) quinazolinone-1-alkanoic acid derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0138492-A2 | Process for preparing substituted 4-alkyl-2(1H) quinazolinone-1-alkanoic acid derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4490374-A | CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0107398-A1 | Ortho substituted dihydroxy-2(1H)quinazolinone-1-alkanoic acids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1984-05-02 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | KDM4E 4523/4885HTT 4450/4885CYP3A4 2626/4885 |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | KDM4E 3129/4885HTT 3735/4885CYP3A4 2491/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | KDM4E 3129/4885HTT 3735/4885CYP3A4 2491/4885 |
| US-20240139125-A1 | BI-1 ANTAGONISTS AND THEIR USES | TMBIM6, RPS6KB1, RACK1 | KDM4E 2423/4885HTT 3125/4885CYP3A4 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.